#Riliprubart
LightNews LightNews
reuters.com
Sanofi ends Phase 3 riliprubart trial after weak interim results reut.rs/4aCQ3m8
Sanofi ends Phase 3 riliprubart trial after weak interim results
Biopharmaceutical company Sanofi will stop a Phase ​3 trial of its drug ‌riliprubart for a rare neurological condition after an interim ​analysis of the ​study found it unlikely to ⁠provide sufficient efficacy.
reut.rs
June 10, 2026 at 11:35 AM
pharmaphorum.bsky.social
#Sanofi's #neurology pipeline has had a hole blown in it after a phase 3 trial of #riliprubart (SAR445088) in #raredisease chronic inflammatory demyelinating polyneuropathy (#CIDP) was stopped for futility.

pharmaphorum.com/news/sanofi-...
Sanofi abandons phase 3 trial of neurology drug riliprubart
Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart in rare disease CIDP was stopped for futility.
pharmaphorum.com
June 10, 2026 at 9:40 AM
wizybit.bsky.social
2/6 net-positive signal despite one significant setback.

The standout: riliprubart advanced to Phase 3 in chronic inflammatory demyelinating polyneuropathy (CIDP), now active and no longer recruiting—a sign of mature patient enrollment and readiness for pivotal testing.
August 11, 2026 at 1:25 PM
kidneystories.bsky.social
FDA grants orphan drug designation to antibody-mediated rejection treatment - Pharmafile - goo.gl/alerts/vuvMrr #GoogleAlerts
FDA grants orphan drug designation to antibody-mediated rejection treatment - Pharmafile
Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to riliprubart for the treatment of
goo.gl
June 26, 2025 at 11:00 PM
qiancx.bsky.social
赛诺菲新药Riliprubart获FDA孤儿药资格 助力罕见移植排斥反应治疗迎来新希望

https://qian.cx/posts/C910B87F-2E93-4416-840A-6971B1912DFB
October 10, 2025 at 8:44 PM
notreload.bsky.social
#$SNY discontinues its Phase 3 MOBILIZE study of riliprubart in refractory CIDP after failing to show efficacy. The setback raises major doubts for #$DNTH claseprubart (C1s inhibitor). notreload.xyz/xy/sanofi-dr...
Sanofi Drops Phase 3 Riliprubart Trial in CIDP, Dianthus Plunges
Sanofi discontinues its Phase 3 MOBILIZE study of riliprubart in refractory CIDP after failing to show efficacy. The setback raises major doubts for Dianthus’ claseprubart (C1s inhibitor).
notreload.xyz
June 10, 2026 at 11:02 AM
educativ.bsky.social
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/52724...
February 3, 2026 at 5:23 AM
educativ.bsky.social
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/52724...
February 3, 2026 at 1:07 AM
educativ.bsky.social
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
December 23, 2025 at 7:02 AM
educativ.bsky.social
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
December 23, 2025 at 4:31 AM
educativ.bsky.social
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
December 23, 2025 at 3:27 AM
educativ.bsky.social
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
December 23, 2025 at 3:21 AM
educativ.bsky.social
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
December 23, 2025 at 3:16 AM
educativ.bsky.social
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
December 23, 2025 at 3:15 AM
educativ.bsky.social
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
December 23, 2025 at 2:12 AM
educativ.bsky.social
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/50512...
December 23, 2025 at 1:43 AM
educativ.bsky.social
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/47927...
November 2, 2025 at 9:59 AM
educativ.bsky.social
Global Medical Director, Riliprubart - Cambridge Job educativ.net/jobs/job/47927...
November 2, 2025 at 2:21 AM
educativ.bsky.social
Senior Global Marketing Manager, Riliprubart - Cambridge Job educativ.net/jobs/job/37992...
May 21, 2025 at 6:41 AM
educativ.bsky.social
Senior Global Marketing Manager, Riliprubart - Cambridge Job educativ.net/jobs/job/37992...
May 21, 2025 at 4:42 AM
educativ.bsky.social
Senior Global Marketing Manager, Riliprubart - Cambridge Job educativ.net/jobs/job/37992...
May 21, 2025 at 2:55 AM
educativ.bsky.social
Senior Global Marketing Manager, Riliprubart - Cambridge Job educativ.net/jobs/job/37992...
May 21, 2025 at 2:11 AM
educativ.bsky.social
Senior Global Marketing Manager, Riliprubart - Cambridge Job educativ.net/jobs/job/37992...
May 21, 2025 at 1:48 AM
kriptabiz.bsky.social
FDA присвоило статус орфанного препарата Riliprubart компании Sanofi: новые горизонты в лечении редких заболеваний

https://kripta.biz/posts/CD5CD490-B400-4CB0-BA8C-F3E88C44E13C
October 10, 2025 at 8:44 PM
thebiotechtimes.bsky.social
Sanofi's MOBILIZE Phase 3 trial of riliprubart in refractory CIDP has been halted on efficacy grounds. An independent monitoring committee determined the study is unlikely to meet its primary endpoint. No safety signals emerged.
Sanofi halts MOBILIZE Phase 3 trial of riliprubart in refractory CIDP
An independent data monitoring committee found the study unlikely to demonstrate sufficient efficacy; no safety concerns were identified with riliprubart.
biotech.disruptsmedia.com
June 23, 2026 at 9:00 AM